Clinical trial
Feasibility and Efficacy of Molecular Analysis-Directed Individualized Therapy Based of Tumoral mRNA Levels of ERCC1, RRM1 and BRCA1 in Advanced Non-Small-Cell Lung Cancer
NCT00705549 is registered in ClinicalTrials.gov with Hellenic Oncology Research Group as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Feasibility and Efficacy of Molecular Analysis-Directed Individualized Therapy Based of Tumoral mRNA Levels of ERCC1, RRM1 and BRCA1 in Advanced Non-Small-Cell Lung Cancer
- Lead sponsor
- Hellenic Oncology Research Group
- Phase
- Phase 2
- Overall status
- Terminated
- Start date
- February 29, 2008
- Completion date
- September 30, 2011
- Enrollment
- 88 (actual)
- Sites
- 9
Conditions
As the registry lists them; a condition with its own page is linked.
non-small-cell lung cancer